Design Therapeutics Inc
DSGN
Company Profile
Business description
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Contact
6005 Hidden Valley Road
Suite 110
CarlsbadCA92011
USAT: +1 858 293-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
56
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
With a focus on leveraging its AI investments, here’s what we think of Meta stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 15.30 | 0.17% |
| CAC 40 | 7,763.38 | 34.84 | -0.45% |
| DAX 40 | 24,119.80 | 188.00 | -0.77% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 9,012.39 | 0.60 | -0.01% |
| HKSE | 25,130.03 | 135.89 | 0.54% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 39,774.92 | 44.19 | -0.11% |
| NZX 50 Index | 12,833.74 | 127.77 | -0.99% |
| S&P 500 | 6,305.60 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,677.20 | 9.00 | 0.10% |
| SSE Composite Index | 3,581.86 | 22.07 | 0.62% |